These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 17526015

  • 1. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.
    Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M.
    Hepatology; 2007 Jul; 46(1):122-9. PubMed ID: 17526015
    [Abstract] [Full Text] [Related]

  • 2. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I, Sánchez-González C, Martínez R, López-Chaves C, Porres JM, Aranda P, Llopis J, Galisteo M, Zarzuelo A, Errami M, López-Jurado M.
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [Abstract] [Full Text] [Related]

  • 3. Alleviation of hepatic steatosis accompanied by modulation of plasma and liver TNF-alpha levels by Trigonella foenum graecum (fenugreek) seeds in Zucker obese (fa/fa) rats.
    Raju J, Bird RP.
    Int J Obes (Lond); 2006 Aug; 30(8):1298-307. PubMed ID: 16477270
    [Abstract] [Full Text] [Related]

  • 4. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
    Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P.
    Mol Pharmacol; 2003 Apr; 63(4):908-14. PubMed ID: 12644592
    [Abstract] [Full Text] [Related]

  • 5. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group.
    N Engl J Med; 2005 Nov 17; 353(20):2121-34. PubMed ID: 16291982
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM.
    Kidney Int; 2007 Dec 17; 72(11):1345-57. PubMed ID: 17882151
    [Abstract] [Full Text] [Related]

  • 8. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.
    Am J Physiol Endocrinol Metab; 2014 Feb 15; 306(4):E457-68. PubMed ID: 24381003
    [Abstract] [Full Text] [Related]

  • 9. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A, Del Arco I, Javier Pavón F, Macías M, Perez-Valero V, Rodríguez de Fonseca F.
    Neuropharmacology; 2008 Jan 15; 54(1):226-34. PubMed ID: 17467748
    [Abstract] [Full Text] [Related]

  • 10. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.
    Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM.
    Diabetes Obes Metab; 2005 Jan 15; 7(1):65-72. PubMed ID: 15642077
    [Abstract] [Full Text] [Related]

  • 11. Dietary phosphatidylinositol prevents the development of nonalcoholic fatty liver disease in Zucker (fa/fa) rats.
    Shirouchi B, Nagao K, Inoue N, Furuya K, Koga S, Matsumoto H, Yanagita T.
    J Agric Food Chem; 2008 Apr 09; 56(7):2375-9. PubMed ID: 18324772
    [Abstract] [Full Text] [Related]

  • 12. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
    Chen W, Chen Z, Xue N, Zheng Z, Li S, Wang L.
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug 09; 386(8):721-32. PubMed ID: 23620336
    [Abstract] [Full Text] [Related]

  • 13. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
    Bergholm R, Sevastianova K, Santos A, Kotronen A, Urjansson M, Hakkarainen A, Lundbom J, Tiikkainen M, Rissanen A, Lundbom N, Yki-Järvinen H.
    Int J Obes (Lond); 2013 May 09; 37(5):699-703. PubMed ID: 22828945
    [Abstract] [Full Text] [Related]

  • 14. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.
    Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P.
    Diabetes; 2010 Apr 09; 59(4):926-34. PubMed ID: 20110567
    [Abstract] [Full Text] [Related]

  • 15. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ.
    J Neuroendocrinol; 2008 May 09; 20 Suppl 1():139-46. PubMed ID: 18426513
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L, Pi-Sunyer X, Després JP, McCarthy C, Scheen A.
    Diabetes Care; 2008 Feb 09; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [Abstract] [Full Text] [Related]

  • 17. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.
    Croci T, Zarini E.
    Br J Pharmacol; 2007 Mar 09; 150(5):559-66. PubMed ID: 17245360
    [Abstract] [Full Text] [Related]

  • 18. A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats.
    Gudbrandsen OA, Wergedahl H, Berge RK.
    Nutrition; 2009 May 09; 25(5):574-80. PubMed ID: 19101115
    [Abstract] [Full Text] [Related]

  • 19. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats.
    Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y, Richard D.
    Diabetes; 2006 Dec 09; 55(12):3403-10. PubMed ID: 17130486
    [Abstract] [Full Text] [Related]

  • 20. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG.
    Pharmacol Biochem Behav; 2006 Jun 09; 84(2):353-9. PubMed ID: 16814374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.